サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1468359

ゴーシェ病市場：タイプ、診断・治療、エンドユーザー、地域別、2024～2032年

Gaucher Disease Market by Type (Gaucher Disease Type 1, Gaucher Disease Type 2, Gaucher Disease Type 3, and Others), Diagnosis and Treatment (Diagnosis, Treatment), End User (Hospitals, Specialty Clinics, Homecare, and Others), and Region 2024-2032
出版日: | 発行: IMARC | ページ情報: 英文 138 Pages | 納期: 2～3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=155.13円
ゴーシェ病市場：タイプ、診断・治療、エンドユーザー、地域別、2024～2032年
出版日: 2024年04月08日
発行: IMARC
ページ情報: 英文 138 Pages
納期: 2～3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界のゴーシェ病市場規模は2023年に17億米ドルに達しました。今後、IMARC Groupは、2024～2032年にかけて6.2%の成長率（CAGR）を示し、2032年までに29億米ドルに達すると予測しています。ゴーシェ病患者の増加、広範な研究開発（R&D）活動、薬剤の入手しやすさなどが市場を牽引する主要要因です。

ゴーシェ病は、ライソゾーム貯蔵障害としても知られ、体内の脂肪を分解・貯蔵する能力に影響を及ぼす稀な遺伝性代謝疾患です。体内のグルコセレブロシド脂肪化学物質を分解するグルコセレブロシダーゼの欠損によって引き起こされます。脾臓や肝臓の肥大、貧血、あざができやすく出血しやすい、肺障害、疲労、発作、骨の異常などを伴います。様々な身体試験、病歴、血液試験や画像試験などの臨床試験、遺伝子の変異の有無を確認する遺伝子試験によって診断されます。ゴーシェ病の治療には、薬剤療法、注射療法、酵素補充療法（ERT）、骨髄移植、基質除去療法（SRT）などが用いられ、症状に伴う痛みを最小限に抑え、生活の質を向上させるのに役立っています。

ゴーシェ病市場の動向：

現在、個人の間で遺伝子異常の有病率が増加し、ゴーシェ病患者数が増加していることは、世界の市場成長を後押しする主要要因の一つです。さらに、これらの医療的障害を発症しやすい高齢化人口の増加が、ゴーシェ病治療に対する需要の増加をもたらしています。さらに、ゴーシェ病治療のための経済的支援を提供し、医療費を削減する健康保険の導入が増加しています。これとは別に、ゴーシェ病、その症状、診断、治療オプションの容易な利用可能性に関する意識の高まりが、市場にプラスの影響を与えています。さらに、各国の政府はゴーシェ病の研究や新しい治療法の開発のために研究開発（R&D）活動に投資しています。また、誰もが利用しやすい質の高い医療施設を提供するための対策にも取り組んでいます。このことは、診断技術の著しい向上と相まって、市場に明るい展望をもたらしています。これに加えて、グルコセレブロシドを分解して蓄積を減少させる経口療法のようなERT治療代替薬が容易に入手可能であるという認識が高まっていることも、市場の成長に寄与しています。一般に、ゴーシェ病に伴う痛みを和らげるために、市販薬（OTC）や処方箋で容易に入手できるジェネリック医薬品が使用されています。

本レポートで扱う主要質問

  • 世界のゴーシェ病市場の規模は？
  • 2024～2032年における世界のゴーシェ病市場の予想成長率は？
  • 世界のゴーシェ病市場を牽引する主要因は何か？
  • COVID-19が世界のゴーシェ病市場に与えた影響は？
  • タイプ別の世界のゴーシェ病市場内訳は？
  • 世界のゴーシェ病市場における主要地域は？
  • 世界のゴーシェ病市場における主要参入企業は？

目次

第1章 序文

第2章 調査範囲と調査手法

  • 調査目的
  • 利害関係者
  • データソース
    • 一次情報
    • 二次情報
  • 市場推定
    • ボトムアップアプローチ
    • トップダウンアプローチ
  • 調査手法

第3章 エグゼクティブサマリー

第4章 イントロダクション

  • 概要
  • 主要産業動向

第5章 世界のゴーシェ病市場

  • 市場概要
  • 市場実績
  • COVID-19の影響
  • 市場予測

第6章 市場内訳：タイプ別

  • ゴーシェ病1型
  • ゴーシェ病2型
  • ゴーシェ病3型
  • その他

第7章 市場内訳：診断・治療別

  • 診断
    • 市場動向
    • 主要セグメント
      • 健康診断
      • 血液試験
      • 画像試験
      • 妊娠前スクリーニングと出生前試験
      • その他
    • 市場予測
  • 治療
    • 市場動向
    • 主要セグメント
      • 手術
      • 薬剤療法
      • その他
    • 市場予測

第8章 市場内訳：エンドユーザー別

  • 病院
  • 専門クリニック
  • 在宅医療
  • その他

第9章 市場内訳：地域別

  • 北米
    • 米国
    • カナダ
  • アジア太平洋
    • 中国
    • 日本
    • インド
    • 韓国
    • オーストラリア
    • インドネシア
    • その他
  • 欧州
    • ドイツ
    • フランス
    • 英国
    • イタリア
    • スペイン
    • ロシア
    • その他
  • ラテンアメリカ
    • ブラジル
    • メキシコ
    • その他
  • 中東・アフリカ
    • 市場動向
    • 市場内訳：国別
    • 市場予測

第10章 促進要因、抑制要因、機会

  • 市場概要
  • 促進要因
  • 抑制要因
  • 機会

第11章 バリューチェーン分析

第12章 ポーターのファイブフォース分析

  • 概要
  • 買い手の交渉力
  • 供給企業の交渉力
  • 競合の程度
  • 新規参入業者の脅威
  • 代替品の脅威

第13章 価格分析

第14章 競合情勢

  • 市場構造
  • 主要企業
  • 主要企業のプロファイル
    • ISU Abxis Co. Ltd.
    • Johnson & Johnson
    • Pfizer Inc.
    • Protalix Biotherapeutics
    • Sanofi S.A
    • Takeda Pharmaceutical Company Limited
図表

List of Figures

  • Figure 1: Global: Gaucher Disease Market: Major Drivers and Challenges
  • Figure 2: Global: Gaucher Disease Market: Sales Value (in Billion US$), 2018-2023
  • Figure 3: Global: Gaucher Disease Market Forecast: Sales Value (in Billion US$), 2024-2032
  • Figure 4: Global: Gaucher Disease Market: Breakup by Type (in %), 2023
  • Figure 5: Global: Gaucher Disease Market: Breakup by Diagnosis and Treatment (in %), 2023
  • Figure 6: Global: Gaucher Disease Market: Breakup by End User (in %), 2023
  • Figure 7: Global: Gaucher Disease Market: Breakup by Region (in %), 2023
  • Figure 8: Global: Gaucher Disease (Gaucher Disease Type 1) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 9: Global: Gaucher Disease (Gaucher Disease Type 1) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 10: Global: Gaucher Disease (Gaucher Disease Type 2) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 11: Global: Gaucher Disease (Gaucher Disease Type 2) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 12: Global: Gaucher Disease (Gaucher Disease Type 3) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 13: Global: Gaucher Disease (Gaucher Disease Type 3) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 14: Global: Gaucher Disease (Other Types) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 15: Global: Gaucher Disease (Other Types) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 16: Global: Gaucher Disease (Diagnosis) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 17: Global: Gaucher Disease (Diagnosis) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 18: Global: Gaucher Disease (Treatment) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 19: Global: Gaucher Disease (Treatment) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 20: Global: Gaucher Disease (Hospitals) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 21: Global: Gaucher Disease (Hospitals) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 22: Global: Gaucher Disease (Specialty Clinics) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 23: Global: Gaucher Disease (Specialty Clinics) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 24: Global: Gaucher Disease (Homecare) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 25: Global: Gaucher Disease (Homecare) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 26: Global: Gaucher Disease (Other End Users) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 27: Global: Gaucher Disease (Other End Users) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 28: North America: Gaucher Disease Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 29: North America: Gaucher Disease Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 30: United States: Gaucher Disease Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 31: United States: Gaucher Disease Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 32: Canada: Gaucher Disease Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 33: Canada: Gaucher Disease Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 34: Asia-Pacific: Gaucher Disease Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 35: Asia-Pacific: Gaucher Disease Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 36: China: Gaucher Disease Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 37: China: Gaucher Disease Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 38: Japan: Gaucher Disease Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 39: Japan: Gaucher Disease Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 40: India: Gaucher Disease Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 41: India: Gaucher Disease Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 42: South Korea: Gaucher Disease Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 43: South Korea: Gaucher Disease Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 44: Australia: Gaucher Disease Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 45: Australia: Gaucher Disease Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 46: Indonesia: Gaucher Disease Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 47: Indonesia: Gaucher Disease Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 48: Others: Gaucher Disease Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 49: Others: Gaucher Disease Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 50: Europe: Gaucher Disease Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 51: Europe: Gaucher Disease Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 52: Germany: Gaucher Disease Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 53: Germany: Gaucher Disease Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 54: France: Gaucher Disease Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 55: France: Gaucher Disease Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 56: United Kingdom: Gaucher Disease Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 57: United Kingdom: Gaucher Disease Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 58: Italy: Gaucher Disease Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 59: Italy: Gaucher Disease Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 60: Spain: Gaucher Disease Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 61: Spain: Gaucher Disease Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 62: Russia: Gaucher Disease Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 63: Russia: Gaucher Disease Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 64: Others: Gaucher Disease Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 65: Others: Gaucher Disease Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 66: Latin America: Gaucher Disease Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 67: Latin America: Gaucher Disease Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 68: Brazil: Gaucher Disease Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 69: Brazil: Gaucher Disease Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 70: Mexico: Gaucher Disease Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 71: Mexico: Gaucher Disease Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 72: Others: Gaucher Disease Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 73: Others: Gaucher Disease Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 74: Middle East and Africa: Gaucher Disease Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 75: Middle East and Africa: Gaucher Disease Market: Breakup by Country (in %), 2023
  • Figure 76: Middle East and Africa: Gaucher Disease Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 77: Global: Gaucher Disease Industry: Drivers, Restraints, and Opportunities
  • Figure 78: Global: Gaucher Disease Industry: Value Chain Analysis
  • Figure 79: Global: Gaucher Disease Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Gaucher Disease Market: Key Industry Highlights, 2023 & 2032
  • Table 2: Global: Gaucher Disease Market Forecast: Breakup by Type (in Million US$), 2024-2032
  • Table 3: Global: Gaucher Disease Market Forecast: Breakup by Diagnosis and Treatment (in Million US$), 2024-2032
  • Table 4: Global: Gaucher Disease Market Forecast: Breakup by End User (in Million US$), 2024-2032
  • Table 5: Global: Gaucher Disease Market Forecast: Breakup by Region (in Million US$), 2024-2032
  • Table 6: Global: Gaucher Disease Market: Competitive Structure
  • Table 7: Global: Gaucher Disease Market: Key Players
目次
Product Code: SR112024A6807

The global Gaucher disease market size reached US$ 1.7 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 2.9 Billion by 2032, exhibiting a growth rate (CAGR) of 6.2% during 2024-2032. Increasing number of patients suffering from Gaucher disease, extensive research and development (R&D) activities, and the easy availability of drugs represent some of the key factors driving the market.

Gaucher disease, also known as lysosomal storage disorder, is a rare genetic metabolic disorder that affects the ability of the body to break down and store fats. It is caused by glucocerebrosidase deficiency, which breaks down glucocerebroside fatty chemicals in the body. It is associated with an enlarged spleen and liver, anemia, easy bruising and bleeding, lung problems, fatigue, seizures, and bone abnormalities. It is diagnosed through various physical examinations, medical history, and laboratory tests, such as blood and imaging tests, and genetic testing to confirm the presence of a mutation in the gene. Gaucher disease can be treated using medications, injections, enzyme replacement therapy (ERT), bone marrow transplantation, and substrate reduction therapy (SRT), which aid in minimizing the pain associated with the symptoms and improve the quality of life.

Gaucher Disease Market Trends:

At present, the increasing prevalence of genetic abnormalities among individuals and the rising number of patients suffering from Gaucher disease represent one of the major factors bolstering the market growth around the world. Moreover, the growing aging population that is more prone to developing these medical disorders is resulting in an increasing demand for Gaucher disease treatment. In addition, there is a rise in the implementation of health insurance policies that provide financial assistance for Gaucher disease treatment and reduce medical expenses. Apart from this, the growing awareness about Gaucher disease, its symptoms, diagnosis, and the easy availability of the treatment options is influencing the market positively. Furthermore, governments of numerous countries are investing in research and development (R&D) activities to study Gaucher disease and develop new treatments. They are also undertaking measures to offer quality healthcare facilities that are accessible to all. This, coupled with significant improvements in the diagnostic technologies, is creating a positive outlook for the market. Besides this, the rising awareness about the easy availability of ERT treatment alternatives like oral therapies that help break down glucocerebroside and reduce the accumulation is contributing to the growth of the market. They generally involve generic drugs that are readily available over the counter (OTC) and by prescription for relieving pain associated with Gaucher disease.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the global Gaucher disease market, along with forecasts at the global, regional, and country level from 2024-2032. Our report has categorized the market based on type, diagnosis and treatment, and end user.

Type Insights:

Gaucher Disease Type 1

Gaucher Disease Type 2

Gaucher Disease Type 3

Others

The report has provided a detailed breakup and analysis of the Gaucher disease market based on the type. This includes Gaucher disease type 1, Gaucher disease type 2, Gaucher disease type 3, and others. According to the report, Gaucher disease type 1 represented the largest segment.

Diagnosis and Treatment Insights:

Diagnosis

Physical Exam

Blood Tests

Imaging Tests

Preconception Screening and Prenatal Testing

Others

Treatment

Surgery

Medication

Others

A detailed breakup and analysis of the Gaucher disease market based on the diagnosis and treatment has also been provided in the report. This includes diagnosis (physical exam, blood tests, imaging tests, preconception screening and prenatal testing, and others) and treatment (surgery, medication, and others).

End User Insights:

Hospitals

Specialty Clinics

Homecare

Others

The report has provided a detailed breakup and analysis of the Gaucher disease market based on the end user. This includes hospitals, specialty clinics, homecare, and others.

Regional Insights:

North America

United States

Canada

Asia-Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

The report has also provided a comprehensive analysis of all the major regional markets that include North America (the United States and Canada), Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others), Europe (Germany, France, United Kingdom, Italy, Spain, Russia, and others), Latin America (Brazil, Mexico, and others), and the Middle East and Africa. According to the report, North America was the largest market for Gaucher disease. Some of the factors driving the North America Gaucher disease market included increasing prevalence of genetic abnormalities, the presence of a well-established healthcare infrastructure, the integration of advanced medical technologies, etc.

Competitive Landscape:

The report has also provided a comprehensive analysis of the competitive landscape in the global Gaucher disease market. Detailed profiles of all major companies have also been provided. Some of the companies covered include ISU Abxis Co. Ltd., Johnson & Johnson, Pfizer Inc., Protalix Biotherapeutics, Sanofi S.A, Takeda Pharmaceutical Company Limited, etc. Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

Key Questions Answered in This Report

  • 1. How big is the global Gaucher disease market?
  • 2. What is the expected growth rate of the global Gaucher disease market during 2024-2032?
  • 3. What are the key factors driving the global Gaucher disease market?
  • 4. What has been the impact of COVID-19 on the global Gaucher disease market?
  • 5. What is the breakup of the global Gaucher disease market based on the type?
  • 6. What are the key regions in the global Gaucher disease market?
  • 7. Who are the key players/companies in the global Gaucher disease market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Gaucher Disease Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Type

  • 6.1 Gaucher Disease Type 1
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Gaucher Disease Type 2
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Gaucher Disease Type 3
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Others
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast

7 Market Breakup by Diagnosis and Treatment

  • 7.1 Diagnosis
    • 7.1.1 Market Trends
    • 7.1.2 Key Segments
      • 7.1.2.1 Physical Exam
      • 7.1.2.2 Blood Tests
      • 7.1.2.3 Imaging Tests
      • 7.1.2.4 Preconception Screening and Prenatal Testing
      • 7.1.2.5 Others
    • 7.1.3 Market Forecast
  • 7.2 Treatment
    • 7.2.1 Market Trends
    • 7.2.2 Key Segments
      • 7.2.2.1 Surgery
      • 7.2.2.2 Medication
      • 7.2.2.3 Others
    • 7.2.3 Market Forecast

8 Market Breakup by End User

  • 8.1 Hospitals
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Specialty Clinics
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Homecare
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast
  • 8.4 Others
    • 8.4.1 Market Trends
    • 8.4.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia-Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 Drivers, Restraints, and Opportunities

  • 10.1 Overview
  • 10.2 Drivers
  • 10.3 Restraints
  • 10.4 Opportunities

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 ISU Abxis Co. Ltd.
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
      • 14.3.1.3 Financials
    • 14.3.2 Johnson & Johnson
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
      • 14.3.2.3 Financials
      • 14.3.2.4 SWOT Analysis
    • 14.3.3 Pfizer Inc.
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
      • 14.3.3.3 Financials
      • 14.3.3.4 SWOT Analysis
    • 14.3.4 Protalix Biotherapeutics
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
      • 14.3.4.3 Financials
    • 14.3.5 Sanofi S.A
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio
      • 14.3.5.3 Financials
      • 14.3.5.4 SWOT Analysis
    • 14.3.6 Takeda Pharmaceutical Company Limited
      • 14.3.6.1 Company Overview
      • 14.3.6.2 Product Portfolio
      • 14.3.6.3 Financials
      • 14.3.6.4 SWOT Analysis

Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.